Physician profile
Raul A Pena
NPI 1164456943
$6,829.01
in general payments reported to CMS, 2019-2025
25 companies · $476 in 2025
The $476 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,140 · 2020: $675 · 2021: $1,075 · 2022: $1,585 · 2023: $1,314 · 2024: $564 · 2025: $476.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,329 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,329.14 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $1,824.06 | 2022-2025 | Envista Mx60 Iol, Envista Envy Iol, Ic-8 Apthera Iol |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $1,108.64 | 2019-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $782.31 | 2019-2023 | Ifs Advanced Femtosec Laser, Catalys System |
| Alcon Vision LLC | $609.62 | 2019-2025 | Wavelight Refractive Suite, Argos, Rocklatan |
| Sight Sciences, INC. | $554.61 | 2022-2025 | Omni Surgical System |
| Rxsight INC | $428.08 | 2021-2024 | Rxsight Injector Handpiece, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Carl Zeiss Meditec, INC. | $238.87 | 2019-2023 | |
| Carl Zeiss Meditec USA, INC. | $173.39 | 2022-2025 | Cirrus Hd-Oct |
| Oyster Point Pharma, INC. | $136.87 | 2022-2023 | Tyrvaya |
| Glaukos Corporation | $132.10 | 2021 | |
| Beaver-Visitec International, INC. | $114.82 | 2021 | |
| Genentech USA, INC. | $111.17 | 2019 | |
| Eyevance Pharmaceuticals LLC | $103.54 | 2019-2020 | |
| Bausch Health US, LLC | $102.44 | 2020 | |
| Abbvie INC. | $73.74 | 2023-2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $68.15 | 2024-2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $59.22 | 2020 | |
| Biotissue Holdings INC. | $40.18 | 2020 | |
| Kala Pharmaceuticals, INC. | $34.67 | 2019 | |
| Harrow Eye, LLC | $31.05 | 2025 | |
| Allergan, INC. | $30.78 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $25.51 | 2020-2021 | |
| Shire North American Group INC | $16.98 | 2019 | |
| Lkc Technologies, INC. | $16.00 | 2025 | |
| Aerie Pharmaceuticals, INC. | $12.21 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raul Pena listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.